Melanocortin

Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors

Retrieved on: 
Thursday, March 28, 2024
Dermatology, Vitiligo, Growth, Science, History, Female, American Academy, Light, Skin, Melanocortin, Depigmentation, Peptide

DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine.

Key Points: 
  • DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine.
  • Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf.
  • CLINUVEL is now investing heavily in R&D with an ambitious clinical pipeline, including a phase III clinical trial for the pigment loss disorder vitiligo.
  • “German investors have been pivotal in supporting our work thus far and we hope to share our success with the wider investment community.”

Malibu shines a light on CLINUVEL’s pioneering work in photomedicine

Retrieved on: 
Tuesday, March 5, 2024
Skin cancer, EPP, Pigment, Nervous system, Attacca Quartet, Growth, XP, Skin, Xeroderma pigmentosum, Global health, Life, Parker, Risk, Health, Vitiligo, Peptide, Melanocortin, Patient, Medicine, Knowledge, Research, Brain, Pharmaceutical industry

The Group’s CEO Dr. Philippe Wolgen also unveiled what is next for the most exciting biopharmaceutical firm in the field of photomedicine today.

Key Points: 
  • The Group’s CEO Dr. Philippe Wolgen also unveiled what is next for the most exciting biopharmaceutical firm in the field of photomedicine today.
  • Philanthropy is central to the work of Lady Gaga and Michael Polansky, Sean Parker and Alexandra Parker.
  • At the event in Malibu, CLINUVEL announced the Photomedicine Foundation, which will count Mr Polansky as a trustee.
  • CLINUVEL is grateful to have their support as we translate our pharmaceutical technology into PhotoCosmetics and give back to underserved communities.

Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment

Retrieved on: 
Monday, October 16, 2023
NYSE, Inflammation, Safety, United European Gastroenterology, Bremelanotide, Colitis, DSS, Inflammatory bowel disease, UEG, Melanocortin, Conference, Patient, Poster, Pharmaceutical industry, Rat, Palatine

The poster is currently available on the UEG 2023 Conference website.

Key Points: 
  • The poster is currently available on the UEG 2023 Conference website.
  • "This important mechanism of action data supports our active business development efforts for PL8177, including continued enrollment of patients in a Phase 2 ulcerative colitis study."
  • The poster presents data from a series of oral PL8177 dose-ranging studies in the DSS colon inflammation model and includes histological, genomic, and proteomic data.
  • PL8177 treatment showed clear evidence of resolving pathological inflammation by repolarizing colon macrophages from a pro-inflammatory to a pro-inflammation resolving state.

Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference

Retrieved on: 
Tuesday, May 9, 2023
Melanocortin, PTN, Abstract, Gastrointestinal disease, Rat, ASGE, Society, Senior, Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, SSAT, Gastrointestinal Endoscopy, American Association for the Study of Liver Diseases, Research, Medicine, Inflammation, Endoscopy, AASLD, Ulcerative colitis, Extrapyramidal system, Inflammatory bowel disease, DDW, Potential, AGA, Patient, Hepatology, Physician, Dog, Bremelanotide, Poster, NYSE, Pharmaceutical industry, Palatine, GI

CRANBURY, N.J., May 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of the poster "Efficacy of the Melanocortin Receptor Agonist PL8177 as a Potential Therapy for Gastrointestinal Inflammatory Diseases" at the Digestive Disease Week annual meeting May 6-9, 2023 in Chicago, Illinois. The poster was presented by John Dodd, Ph.D., Senior Vice President of Preclinical Research at Palatin. The poster can be found on Palatin's website www.palatin.com.

Key Points: 
  • In preclinical studies in rat models of ulcerative colitis, oral PL8177 was found to be efficacious in reducing colonic damage and inflammation.
  • Clinical data presented in the poster shows that oral PL8177 was released in the GI tract and did not reach systemic circulation.
  • "We are looking forward to the data from an ongoing phase 2 study and the potential of PL8177 as a novel treatment for inflammatory bowel disease."
  • Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma

Retrieved on: 
Tuesday, April 25, 2023
Neuroprotection, Glaucoma, Latanoprost, Melanocortin, ARVO, Association for Research in Vision and Ophthalmology, IOP, Timolol, CMO, Intraocular pressure, MD, Patient, Bremelanotide, Rabbit, Poster, Research, FDA, Conference, NYSE, Pharmaceutical industry, Palatine, Ophthalmology

CRANBURY, N.J., April 25, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of a poster entitled, Melanocortin Receptor Agonist PL9588 Reduces Intraocular Pressure in Normotensive Rabbits at the Association of Research in Vision and Ophthalmology (ARVO) Annual Conference. The authors of the poster are Paul S. Kayne, Ph.D.; Alison Obr, Ph.D.; John H. Dodd, Ph.D.; Carl Spana, Ph.D., all of Palatin Technologies. The poster was presented by Paul Kayne, Ph.D. on April 24, 2023 at the ARVO conference in New Orleans and will be available on Palatin's website at www.palatin.com.

Key Points: 
  • The poster was presented by Paul Kayne, Ph.D. on April 24, 2023 at the ARVO conference in New Orleans and will be available on Palatin's website at www.palatin.com .
  • "The Palatin research team continues to produce groundbreaking data regarding melanocortins' utility and mechanism of action in treating ocular inflammatory diseases," said Carl Spana, Ph.D., President and CEO of Palatin.
  • "We are excited by the potential of PL9588 as a novel treatment for glaucoma and pending resources, plan to move into clinical development."
  • Palatin's data provides support for continued development of PL9588 with the aim of providing a novel, once-daily treatment for glaucoma.

Global SCENESSE® demand drives increased CLINUVEL revenues, earnings

Retrieved on: 
Thursday, February 23, 2023
Climate, Accounting, Investment, Patient, History, Prescription, Report, Melanocortin, Cryptocurrency, Pharmaceutical industry

For the six months ended 31 December 2022, CLINUVEL is pleased to record a 19% increase in its revenues, and 94% increase in net earnings after tax, or $11.39 million.

Key Points: 
  • For the six months ended 31 December 2022, CLINUVEL is pleased to record a 19% increase in its revenues, and 94% increase in net earnings after tax, or $11.39 million.
  • “The number of prescriptions for, patients receiving, and expert centres administering the therapy have all increased over the period.
  • As of 31 December, CLINUVEL held cash and cash equivalents of over $140 million, a 16% increase from 30 June, with total assets above $160 million.
  • “We have actively managed CLINUVEL’s commercial programs, translating to a steady increase in liquid assets, as well as earnings per share,” Mr Keamy said.

CLINUVEL Trial Results Show Drug Reduces DNA Damage

Retrieved on: 
Sunday, January 15, 2023
EPP, Swelling, Afamelanotide, Skin cancer, Sunburn, Xeroderma pigmentosum, DNA, Stress (linguistics), Xeroderma, Skin, Risk, DNA repair, Patient, Hormone, Physician, Life expectancy, Clinical trial, Melanocortin, Pigment, Inflammation, XP, Light, Disorder, Pharmaceutical industry, Dietary supplement, Black Beach

MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of skin cancers.

Key Points: 
  • MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of skin cancers.
  • The trial results are the first showing the potential of afamelanotide, a melanocortin drug under development by CLINUVEL, to protect and treat patients with xeroderma pigmentosum (XP), a rare disorder which causes extreme rates of skin cancers and forces patients to live in the dark.
  • “Our first clinical trial results demonstrate that afamelanotide in adult XP patients can reduce key markers of light and ultraviolet DNA damage, suggesting we may be able to reduce the risk and frequency of skin cancers in these patients.”
    Xeroderma pigmentosum affects patients’ ability to repair DNA skin damage following exposure to light, particularly ultraviolet (UV) radiation.
  • Note to media: CLINUVEL has released further investor and technical releases on results from the CUV156 study.

Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference

Retrieved on: 
Thursday, September 29, 2022
Securities Exchange Act of 1934, American Academy, Inflammation, AAO, ASCRS, Academy, American Society of Cataract and Refractive Surgery, Twitter, NYSE, Retina, FDA, Refractive surgery, PTN, Drug Quality and Security Act, Duane syndrome, Association, Society, Private Securities Litigation Reform Act, Partnership, Securities Act of 1933, Calendar, DED, Metabolism, Biology, U.S. Securities and Exchange Commission, Patient, Melanocortin, Eye, Physician, Technology, Quality of life, Cataract, Tissue, Surgeon, Genomics, Biotechnology, Security (finance), Proteomics, Marketing, American Academy of Ophthalmology, Multimedia, 5-HT receptor, Kidney, Education, View, Video game, Pharmaceutical industry, Hospital, Palatine (disambiguation), Bremelanotide

CRANBURY, N.J., Sept. 29, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced that Paul Kayne, Ph.D., Vice President of Biological Sciences at Palatin, presented today at the Eyecelerator@AAO in Chicago, IL. The presentation was one of several in the "Eyecelerator@ AAO 2022 - Therapeutics Showcase" general session.

Key Points: 
  • The presentation was one of several in the "Eyecelerator@ AAO 2022 - Therapeutics Showcase" general session.
  • For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com and follow Palatin on Twitter at @PalatinTech.
  • Palatin is not responsible for updating for events that occur after the date of this press release.
  • Palatin Technologies and Vyleesi are registered trademarks of Palatin Technologies, Inc.
    View original content to download multimedia: https://www.prnewswire.com/news-releases/palatin-announces-presentation-...

CLINUVEL progresses vitiligo treatment program

Retrieved on: 
Tuesday, May 10, 2022
Linda, Light therapy, JAMA Dermatology, COVID-19, Treatment, Randomness, American Academy of Dermatology, Immune system, Narrowband, Union, GLOBE, EPP, IRB, Peptide, Afamelanotide, Food, Physician, Safety, Patient, Institutional review board, Phototoxicity, Program, ADR, FDA, Adult, Anaphylaxis, Family, US Foods, DNA, History, Skin, Burns, Health, Quality of life, ASX, Erythropoietic protoporphyria, American Academy, Disease, Melanocortin, CUV, DNA repair, Mental health, Melanocyte, Research, Bourke Street, Melbourne, Mazda North American Operations, Pharmaceutical industry, Medical device, Dermatology, Vitiligo

The drug afamelanotide approved by US and European regulators for a rare light intolerance disorder is being evaluated by Australian company CLINUVEL as a treatment for vitiligo patients with darker skin types.

Key Points: 
  • The drug afamelanotide approved by US and European regulators for a rare light intolerance disorder is being evaluated by Australian company CLINUVEL as a treatment for vitiligo patients with darker skin types.
  • Treatment options remain limited, with no treatments for repigmentation of vitiligo currently approved by the US Food and Drug Administration (FDA).
  • Therefore we have chosen to focus on this patient group, with the highest unmet need, as our clinical program progresses, Dr Teng said.
  • Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians.

Palatin to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference

Retrieved on: 
Monday, May 2, 2022
COVID-19, Calendar, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Pain, 5-HT receptor, Securities Exchange Act of 1934, Biotechnology, NDA, Kidney, Red, Physician, ARVO, Securities Act of 1933, Eye, Irritation, Metabolism, Patient, Security (finance), Conjunctiva, Clinical trial, Animal, Program, FDA, DED, Inflammation, Drug Quality and Security Act, Dry, Tissue, Quality of life, Marketing, Cornea, Disease, Melanocortin, View, Technology, Research, Multimedia, Lubrication, Pharmaceutical industry, Bremelanotide, Palatine (disambiguation)

CRANBURY, N.J., May 2, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Conference being held May 1-4 in Denver.

Key Points: 
  • Palatin previously announced positive results in its Phase 2 study of PL9643 for the treatment of DED.
  • If the program progresses as planned, an NDA submission is targeted for the first half of calendar year 2024.
  • ARVO is the largest and most respected eye and vision research organization in the world.
  • Palatin is not responsible for updating for events that occur after the date of this press release.